Navigation Links
Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Date:4/25/2008

serious adverse events in doses up to 3000 mg.

R7128 demonstrated potent, dose-dependent antiviral activity across four prior treatment-failure patient cohorts (n=40) receiving 750 mg or 1500 mg administered either once-daily or twice-daily for 14 days as monotherapy. The greatest mean decrease in HCV RNA from baseline was demonstrated in the patient cohort that received 1500 mg twice-daily, the highest dose of R7128 administered in the study. These patients demonstrated a mean 2.7 log10 IU/mL (>99%) decrease in HCV RNA. There was no evidence of the development of viral resistance in any dose cohort after 14 days of dosing.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration wi
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
2. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
3. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
6. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
7. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
8. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
9. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
10. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
11. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 18, 2014  Decision ... the United States will increase ... Growth will be primarily driven by expansion in the ... direct energy devices will be increasingly adopted due to ... launched. Other key findings from Decision Resources ...
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
(Date:12/19/2014)... Diet Doc strives to continue to ... weight loss by combining scientific fast weight ... the company understand that remaining committed to a diet ... carbohydrates and sugars from the diet can cause patients ... weight loss goals. , For this reason, Diet ...
(Date:12/19/2014)... December 19, 2014 B. E. Smith, ... healthcare providers, has been retained to lead a national ... Medical Center in Estes Park, Colo. The top executive ... has recently placed more than 900 healthcare executives into ... a 25-bed, not-for-profit critical access hospital and level IV ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 The ... shifting, capital equipment market that is saturated with ... safety and efficacy as well as non-invasive nature, ... were first introduced to the healthcare market. Rapid ... development of MRI safe technologies have greatly expanded ...
(Date:12/19/2014)... Hands On Mobile Spa, has announced they now have a ... been transformed into a utopia for the Long Island community ... The Virtual Tour showcases the beauty of the Spa On ... more. , The Virtual Tour shows viewers each of the ... overhauled Winnebago. Marla Kaplan-Pelle, Director states " It's hard to ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 If you ... having difficulty breathing, you probably wished you had an ... asthma, COPD, cystic fibrosis, and other breathing disorders. Currently, ... medications and avoiding triggers, but other common treatments do ... Educators conference in San Antonio, TX, 34 asthma educators ...
Breaking Medicine News(10 mins):Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 2Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 3Health News:Diet Doc Incorporates Appetite Zap into their Already Impressive Collection of Diet Products to Jump Start the Metabolism and Burn Fat 4X Faster 4Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 2Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 4Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3
... in Huntingtons disease take place earlier in cell life ... Medicine in Houston in a report that appears in ... research provides evidence of toxicity by huntingtin (the protein ... said Dr. Juan Botas, associate professor of molecular and ...
... study finds, , , WEDNESDAY, Jan. 9 (HealthDay News) -- It ... such as schizophrenia and bipolar disorder, very early in the ... five factors that were often present prior to the diagnosis ... high risk of such disorders. When three or more of ...
... Time for the Holiday ... ... 50%,of his yearly weight gain during the Holiday Season. That,s not good ... http://www.metabothin.net ), the herbal weight loss formula,from American Generic Laboratories, specifically designed ...
... Margolin Named President of Blue Cross of California, ... today announced that Brian A. Sassi has been ... Consumer Business Unit, which,includes the Individual, Senior and ... of Blue Cross of California, replaces Joan,Herman, who ...
... on Ice Skating Admission Through ... the End of the Season, PHILADELPHIA, ... and head outdoors this weekend for the,Healthy Kids Fest at the Blue ... for families to enjoy the winter,months, the skating season is in full ...
... 9. 2008 -- Two Hebrew University of Jerusalem researchers, ... awarded the 2008 Wolf Prize in Medicine for their ... cancer research. , Minister of Education Prof. Yuli ... the $100,000 prize, often referred to as Israels Nobel ...
Cached Medicine News:Health News:5 Factors Help Predict Psychosis in Children 2Health News:5 Factors Help Predict Psychosis in Children 3Health News:Metabothin B56 with Ephedra Extract Now Available 2Health News:WellPoint Appoints Brian A. Sassi as President and CEO of the Company's Consumer Business Unit 2Health News:WellPoint Appoints Brian A. Sassi as President and CEO of the Company's Consumer Business Unit 3Health News:Families Encouraged to Enjoy Healthy Kids Fest January 12 at the Blue Cross RiverRink 2Health News:Families Encouraged to Enjoy Healthy Kids Fest January 12 at the Blue Cross RiverRink 3Health News:2 Hebrew University scientists awarded Wolf Prizes 2
Stainless steel lancet blade in stainless steel....
In Stainless steel. Available in 1.5, 2.0,3.0 & 3.5 MM...
AXIOM Multistar is a ceiling-mounted single plane C-Arm system for universal angiography, diagnostics and intervention...
... supports the cardiac workflow through Xper: a ... personalized user settings. In addition Xper integrates ... user interface. For example the interventional tools ... controlled from tableside.,The excellent image quality and ...
Medicine Products: